Novartis' tender offer to acquire all shares of Regulus for $7.00 in cash per share and one contingent value right has expired.
In Basel on June 25, 2025, Novartis made a public statement regarding the conclusion of its tender offer to purchase all outstanding shares of common stock of Regulus Therapeutics Inc. The offer, carried out by Redwood Merger Sub Inc., an indirect wholly owned subsidiary of Novartis, entailed $7.00 in cash per share, along with one contingent value right (CVR) per share. Each CVR represents the entitlement to a contingent payment of $7.00 in cash upon the accomplishment of a regulatory milestone. The offer expired at one minute past 11:59 p.m., New York City Time, on June 24, 2025.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments